The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer.

At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various subtypes of NSCLC.

Eli Lilly and Company has entered into a licensing agreement worth up to $1.26bn with Hanmi Pharm to develop, manufacture and commercialise Hanmi’s biologic drug candidate, sonefpeglutide, worldwide ...

AstraZeneca has secured FDA approval for Imfinzi in combination with BCG induction and maintenance therapy for adults with BCG-naïve, high-risk NMIBC.

J&J’s Rybrevant and cancer vaccines are showing benefit, with detailed data presented at ASCO. Credit: Hindi Studio / Shutterstock.com During the American Society of Clinical Oncology (ASCO) meeting ...

Several companies have presented compelling data from multiple myeloma studies at the 2026 American Society of Clinical Oncology (ASCO) meeting. Data was announced by both Bristol Myers Squibb (BMS) ...

Since Brinsupri’s approval, Insmed has been at the forefront of non-cystic fibrosis bronchiectasis (NCFB), supporting programs to increase disease awareness and to improve clinical outcomes in this ...